Showing 8661-8670 of 10817 results for "".
- Lupus Foundation of America Awards Five Summer Fellowship Grantshttps://practicaldermatology.com/news/lupus-foundation-of-america-awards-five-summer-fellowship-grants/2461899/The Lupus Foundation of America announced five recipients of the
- Research Closes in on the Genetic Factors Underlying HS Riskhttps://practicaldermatology.com/news/research-closes-in-on-the-genetic-factors-underlying-hs-risk/2461893/Researchers have identified genetic locations for increased risk of hidradenitis suppurativa (HS). “This discovery is highly relevant because these changes may effect nearby genes in a way that leads to improper development of hair follicles and predispose them to the rupture,&rdq
- DFD-29 Bests Competition for Papulopustular Rosacea in Adultshttps://practicaldermatology.com/news/dfd-29-bests-competition-for-papulopustular-rosacea-in-adults/2461858/Minocycline Hydrochloride Modified Release Capsules (DFD-29) outperformed Oracea (doxycycline) capsules and placebo for the treatment of moderate-to-severe papulopustular rosacea in adults, according to positive topline results from two Phase 3 studies. Journey Medical&rs
- WCD News: Connect Biopharma's Rademikibart Earns High Marks in ADhttps://practicaldermatology.com/news/wcd-news-connect-biopharmas-rademikibart-earns-high-marks-in-ad/2461851/Four new studies support the efficacy and safety of rademikibart in atopic dermatitis (AD), Connect Biopharma reports. Rademikibart (CBP-201), a next-generation IL-4Rα antibody, achieved all primary and secondary endpoints in a randomized pivotal trial for moderate-to-severe
- Nemolizumab Monotherapy Curbs Itch in Prurigo Nodularis by Week 4https://practicaldermatology.com/news/nemolizumab-monotherapy-curbs-itch-in-prurigo-nodularis-by-week-4/2461840/Nemolizumab monotherapy quickly tames itch in Prurigo Nodularis, according to a late-breaking late-breaking Phase III study presented at the 25th World Congress of Dermatology (WCD) in Singapore. Fully 19.7% of patients treated with nemolizumab monotherapy achieved an itc
- US FDA Nod for Pfizer's Alopecia Drughttps://practicaldermatology.com/news/us-fda-nod-for-pfizers-alopecia-drug/2461814/The US Food and Drug Administration (FDA) approved Litfulo (ritlecitinib, Pfizer Inc) for severe alopecia areata in individuals 12 years of age and older. A kinase inhibitor that targets Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) f
- CHMP Recommends Approval of Leo's Adtralza Pre-filled 2 mL Penhttps://practicaldermatology.com/news/chmp-recommends-approval-of-leos-adtralza-pre-filled-2-ml-pen-5/2461812/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending the approval of Adtralza (tralokinumab) in a (300 mg) 2 mL pre-filled pen. With the pre-filled syringe, a single 300-mg dose given every other week rathe
- Proof of Concept: Oral Orismilast Reduces Pain, Improves Q of L in HShttps://practicaldermatology.com/news/proof-of-concept-oral-orismilast-reduces-pain-improves-q-of-l-in-hs/2461799/Oral orismilast is showing promise in adult with hidradenitis suppurativa (HS), according to positive topline results from the OSIRIS investigator-initiated proof-of-concept study. UNION therapeutics’ Orismilast is a high potency, next-generation PDE4
- Vial, Nielsen BioSciences Partner in Phase III Clinical Trial of Candin for Common Wartshttps://practicaldermatology.com/news/vial-nielsen-biosciences-partner-in-phase-iii-clinical-trial-of-candin-for-common-warts/2461783/Vial is partnering with
- Dermwire Chats with HS Docuseries Host Jasmine Ivanna Espyhttps://practicaldermatology.com/news/directors-cut-dermwire-chats-with-hs-docuseries-director-jasmine-ivanna-espy/2461776/Thanks to a burgeoning pipeline of potential new treatments and new education and awareness efforts, hidradenitis suppurativa (HS) is finally getting the attention that it deserves. Novartis recently premiered a new docuseries on life with HS at the 2023 Tribeca Film Fest